Patents by Inventor Raymond Paxton

Raymond Paxton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods to Determine the Presence of an Antibody that Binds Modified Human Thymic Stromal Lymphopoietin (TSLP)
    Publication number: 20210102955
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: September 14, 2020
    Publication date: April 8, 2021
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
  • METHODS TO DETERMINE THE PRESENCE OF AN ANTIBODY THAT BINDS MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN (TSLP)
    Publication number: 20160377630
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: September 8, 2016
    Publication date: December 29, 2016
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
  • Modified Human Thymic Stromal Lymphopoietin
    Publication number: 20150252089
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: May 20, 2015
    Publication date: September 10, 2015
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
  • Nucleic acids encoding modified human thymic stromal lymphopoietin
    Patent number: 9045558
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: June 2, 2015
    Assignee: IMMUNEX CORPORATION
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
  • Modified Human Thymic Stromal Lymphopoietin
    Publication number: 20140093956
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: December 3, 2013
    Publication date: April 3, 2014
    Applicant: IMMUNEX CORPORATION
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
  • Modified human thymic stromal lymphopoietin
    Patent number: 8598318
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: December 3, 2013
    Assignee: Amgen Inc.
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
  • Pre-Ligand assembly domain of the IL-17 receptor
    Publication number: 20130302886
    Abstract: The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides which inhibit multimerization of a receptor complex comprising an IL-17R family member. Related PLAD-binding polypeptides, chimeric proteins, conjugates, nucleic acids, vectors, host cells, and methods are provided herein.
    Type: Application
    Filed: May 8, 2013
    Publication date: November 14, 2013
    Applicants: RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK, AMGEN INC.
    Inventors: Sarah L. GAFFEN, Fang Shen, Walter Hanel, Jill Kramer, James P. Malone, Michael Wittekind, Raymond Paxton
  • Pre-ligand assembly domain of the IL-17 receptor
    Patent number: 8460647
    Abstract: The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides comprising an amino acid sequence of a domain (e.g., a Fibronectin Ill-like domain) of an IL-17 Receptor (IL-17R) family member, wherein the PLAD polypeptide inhibits multimerization of a receptor complex comprising an IL-17R family member. Also provided are isolated PLAD-binding polypeptides, e.g., antibodies and avimers, which specifically bind to a PLAD polypeptide described herein. Related chimeric proteins, conjugates, nucleic acids, vectors, and host cells are provided herein. Further provided are methods of treating an inflammatory or autoimmune disease, methods of inhibiting IL-17-mediated signal transduction, methods of inhibiting IL-17 ligand binding, methods of inhibiting multimerization of IL-17R complexes, and methods of inhibiting the production of at least one cytokine, chemokine, matrix metalloproteinase, or other molecule associated with IL-17 signal transduction are provided.
    Type: Grant
    Filed: April 20, 2008
    Date of Patent: June 11, 2013
    Assignees: Amgen Inc., Research Foundation of the State University of New York
    Inventors: Sarah L. Gaffen, Fang Shen, Walter Hanel, Jill Kramer, James P. Malone, Michael Wittekind, Raymond Paxton
  • IDENTIFICATION AND METHOD FOR USING THE PRE-LIGAND ASSEMBLY DOMAIN OF THE IL-17 RECEPTOR
    Publication number: 20120009190
    Abstract: The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides comprising an amino acid sequence of a domain (e.g., a Fibronectin Ill-like domain) of an IL-17 Receptor (IL-17R) family member, wherein the PLAD polypeptide inhibits multimerization of a receptor complex comprising an IL-17R family member. Also provided are isolated PLAD-binding polypeptides, e.g., antibodies and avimers, which specifically bind to a PLAD polypeptide described herein. Related chimeric proteins, conjugates, nucleic acids, vectors, and host cells are provided herein. Further provided are methods of treating an inflammatory or autoimmune disease, methods of inhibiting IL-17-mediated signal transduction, methods of inhibiting IL-17 ligand binding, methods of inhibiting multimerization of IL-17R complexes, and methods of inhibiting the production of at least one cytokine, chemokine, matrix metalloproteinase, or other molecule associated with IL-17 signal transduction are provided.
    Type: Application
    Filed: April 20, 2008
    Publication date: January 12, 2012
    Applicant: AMGEN INC.
    Inventors: Sarah L. Gaffen, Fang Shen, Walter Hanel, Jill Kramer, James P. Malone, Michael Wittekind, Raymond Paxton
  • MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN
    Publication number: 20070218523
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: July 23, 2002
    Publication date: September 20, 2007
    Inventors: Stewart Lyman, Kirk Van Ness, Raymond Paxton
  • Antagonists of interleukin-15
    Publication number: 20060057103
    Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R?-subunit and that are incapable of transducing a signal through either the ?- or ?-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the ?- or ?-subunits of the IL-15 receptor complex.
    Type: Application
    Filed: September 7, 2005
    Publication date: March 16, 2006
    Inventors: Kenneth Grabstein, Dean Pettit, Raymond Paxton